Extracellular Vesicles in Atrial Fibrillation—State of the Art

Procyk, Grzegorz; Bilicki, Dominik; Balsam, Paweł; Lodziński, Piotr; Grabowski, Marcin

doi:10.3390/ijms23147591

Cited by 6 publications

(4 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EVs have potential as biomarkers in the diagnosis, prognosis, and monitoring of atherosclerosis in patients and as new therapeutic targets and/or drug delivery vehicles [ 17 ]. It is worth mentioning that altered levels of EVs have been evidenced in patients suffering from atrial fibrillation [ 177 ]. They may be clinically useful as therapeutic targets in cardiovascular diseases.…”

Section: Discussionmentioning

confidence: 99%

Extracellular Vesicles in Atherosclerosis: State of the Art

Olejarz,

Sadowski,

Radoszkiewicz

2023

IJMS

View full text Add to dashboard Cite

Atherosclerosis is a chronic inflammatory disease driven by lipid accumulation in the arteries, leading to narrowing and thrombosis that causes mortality. Emerging evidence has confirmed that atherosclerosis affects younger people and is involved in the majority of deaths worldwide. EVs are associated with critical steps in atherosclerosis, cholesterol metabolism, immune response, endothelial dysfunction, vascular inflammation, and remodeling. Endothelial cell-derived EVs can interact with platelets and monocytes, thereby influencing endothelial dysfunction, atherosclerotic plaque destabilization, and the formation of thrombus. EVs are potential diagnostic and prognostic biomarkers in atherosclerosis (AS) and cardiovascular disease (CVD). Importantly, EVs derived from stem/progenitor cells are essential mediators of cardiogenesis and cardioprotection and may be used in regenerative medicine and tissue engineering.

show abstract

Section: Discussionmentioning

confidence: 99%

Extracellular Vesicles in Atherosclerosis: State of the Art

Olejarz,

Sadowski,

Radoszkiewicz

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…These features allow ease of sample handling and result reproducibility, and thus potentially facilitate translation from bench to bedside use. Multiple studies have identified an association between the content of circulating EVs and AF [ 120 , 121 ]. A study by Shaihov-Teper et al analyzed EVs derived from the epicardial fat of individuals with (n = 32) and without AF (n = 30) [ 122 ].…”

Section: Perspective On Future Areas Of Researchmentioning

confidence: 99%

Obesity-Related Atrial Fibrillation: Cardiac Manifestation of a Systemic Disease

Limpitikul,

Das

2023

JCDD

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common arrhythmia worldwide and is associated with increased morbidity and mortality. The mechanisms underlying AF are complex and multifactorial. Although it is well known that obesity is a strong risk factor for AF, the mechanisms underlying obesity-related AF are not completely understood. Current evidence proposes that in addition to overall hemodynamic changes due to increased body weight, excess adiposity raises systemic inflammation and oxidative stress, which lead to adverse atrial remodeling. This remodeling includes atrial fibrosis, atrial dilation, decreased electrical conduction between atrial myocytes, and altered ionic currents, making atrial tissue more vulnerable to both the initiation and maintenance of AF. However, much remains to be learned about the mechanistic links between obesity and AF. This knowledge will power the development of novel diagnostic tools and treatment options that will help combat the rise of the global AF burden among the obesity epidemic.

show abstract

“…The search for biomarkers enabling diagnosis, prognosis, and treatment response prediction in different cardiovascular diseases has included not only various microparticles, such as micro-ribonucleic acids or extracellular vesicles, but also autoantibodies [21][22][23]. Autoantibodies have been found to target various cardiac receptors modulating the impact of the autonomic nervous system on signaling pathways [7,24].…”

Section: Introductionmentioning

confidence: 99%

Autoantibodies in Atrial Fibrillation—State of the Art

Zygadło

Procyk

Balsam

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. To date, a lot of research has been conducted to investigate the underlying mechanisms of this disease at both molecular and cellular levels. There is increasing evidence suggesting that autoimmunity is an important factor in the initiation and perpetuation of AF. Autoantibodies are thought to play a pivotal role in the regulation of heart rhythm and the conduction system and, therefore, are associated with AF development. In this review, we have summarized current knowledge concerning the role of autoantibodies in AF development as well as their prognostic and predictive value in this disease. The establishment of the autoantibody profile of separate AF patient groups may appear to be crucial in terms of developing novel treatment approaches for those patients; however, the exact role of various autoantibodies in AF is still a matter of ongoing debate.

show abstract

Extracellular Vesicles in Atrial Fibrillation—State of the Art

Cited by 6 publications

References 62 publications

Extracellular Vesicles in Atherosclerosis: State of the Art

Extracellular Vesicles in Atherosclerosis: State of the Art

Obesity-Related Atrial Fibrillation: Cardiac Manifestation of a Systemic Disease

Autoantibodies in Atrial Fibrillation—State of the Art

Contact Info

Product

Resources

About